Skip to main content

Table 1 Chemotherapy dose modifications for haematologic toxicity

From: Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

Haematologic toxicity

Carboplatin

week 2 dose

Paclitaxel

week 2 dose

Absolute neutrophil count less than 1.0

Withhold

Withhold

Platelets less than 75 × 109/L

Withhold

Withhold